Elsevier

Ophthalmology

Volume 92, Issue 3, March 1985, Pages 388-393
Ophthalmology

Visual Loss Following Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

https://doi.org/10.1016/S0161-6420(85)34016-2Get rights and content

Abstract

We reviewed the preoperative, postoperative, and follow-up examinations, fundus photographs, and fluorescein angiograms of 175 eyes of 134 patients with proliferative diabetic retinopathy treated with panretinal photocoagulation. Forty-four (25%) of these eyes lost two or more lines of vision by the time of the last follow-up examination. Follow-ups ranged from 3 to 48 months, with a median follow-up of 15 months. The most common cause of decreased visual acuity was chronic macular edema that had developed following laser treatment, occurring in 14 (8%) eyes. The causes of visual loss following panretinal photocoagulation are discussed.

References (8)

  • MS Mandelcorn et al.

    Pars plana vitrectomy for the management of severe diabetic retinopathy

    Am J Ophthalmol

    (1976)
  • Preliminary report on effects of photocoagulation therapy

    Am J Ophthalmol

    (1976)
  • Photocoagulation treatment of proliferative diabetic retinopathy; the second report of diabetic retinopathy study findings

    Ophthalmology

    (1978)
  • GH Bresnick

    Evaluation and treatment of diabetic retinopathy

    J Cont Ed Ophthalmol

    (1979)
There are more references available in the full text version of this article.

Cited by (119)

  • Nanoparticles as drug delivery agents for managing diabetic retinopathy

    2023, Applications of Multifunctional Nanomaterials
  • Adeno-Associated Viral Vector 2 and 9 Transduction Is Enhanced in Streptozotocin-Induced Diabetic Mouse Retina

    2019, Molecular Therapy Methods and Clinical Development
    Citation Excerpt :

    Diabetic retinopathy (DR) is a chronic progressive disease of the retinal microvasculature associated with prolonged hyperglycemia. Uncontrolled hyperglycemia may lead to proliferative DR (PDR) and diabetic macular edema (DME), which are sight-threatening complications of DR. Pan-retinal photocoagulation has been the standard treatment for PDR since a report from the Diabetic Retinopathy Study,1 but side effects of laser treatment, such as a decreased peripheral visual field and night vision, are still a concern.2,3 After the introduction of anti-vascular endothelial growth factor (VEGF) therapy, intravitreal injection of anti-VEGF agents has been the main treatment for DME.4

View all citing articles on Scopus

Presented at the Eighty-ninth Annual Meeting of the American Academy of Ophthalmology, Atlanta, Georgia, November 11–15, 1984.

View full text